CA2690608C - Methods and compositions for identifying and treating lupus - Google Patents

Methods and compositions for identifying and treating lupus Download PDF

Info

Publication number
CA2690608C
CA2690608C CA2690608A CA2690608A CA2690608C CA 2690608 C CA2690608 C CA 2690608C CA 2690608 A CA2690608 A CA 2690608A CA 2690608 A CA2690608 A CA 2690608A CA 2690608 C CA2690608 C CA 2690608C
Authority
CA
Canada
Prior art keywords
snp
allele
minor allele
snps
lupus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2690608A
Other languages
English (en)
French (fr)
Other versions
CA2690608A1 (en
Inventor
Timothy W. Behrens
Geoffrey Hom
Ward A. Ortmann
Robert Royal Graham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CA2690608A1 publication Critical patent/CA2690608A1/en
Application granted granted Critical
Publication of CA2690608C publication Critical patent/CA2690608C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6858—Allele-specific amplification
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q99/00—Subject matter not provided for in other groups of this subclass
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2533/00—Reactions characterised by the enzymatic reaction principle used
    • C12Q2533/10—Reactions characterised by the enzymatic reaction principle used the purpose being to increase the length of an oligonucleotide strand
    • C12Q2533/101—Primer extension
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Business, Economics & Management (AREA)
  • General Business, Economics & Management (AREA)
  • Animal Behavior & Ethology (AREA)
  • Theoretical Computer Science (AREA)
  • Plant Pathology (AREA)
  • Transplantation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2690608A 2007-05-21 2008-05-21 Methods and compositions for identifying and treating lupus Active CA2690608C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US93915607P 2007-05-21 2007-05-21
US60/939,156 2007-05-21
US1328307P 2007-12-12 2007-12-12
US61/013,283 2007-12-12
PCT/US2008/064430 WO2008144761A2 (en) 2007-05-21 2008-05-21 Methods and compositions for identifying and treating lupus

Publications (2)

Publication Number Publication Date
CA2690608A1 CA2690608A1 (en) 2008-11-27
CA2690608C true CA2690608C (en) 2020-07-21

Family

ID=40122294

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2690608A Active CA2690608C (en) 2007-05-21 2008-05-21 Methods and compositions for identifying and treating lupus

Country Status (14)

Country Link
US (1) US20110046094A1 (enExample)
EP (3) EP2612924B1 (enExample)
JP (4) JP5728226B2 (enExample)
KR (4) KR101947093B1 (enExample)
CN (3) CN104593488B (enExample)
AU (1) AU2008254582A1 (enExample)
BR (1) BRPI0811930B8 (enExample)
CA (1) CA2690608C (enExample)
ES (1) ES2661249T3 (enExample)
HK (1) HK1255086A1 (enExample)
IL (1) IL201949A0 (enExample)
MX (3) MX353428B (enExample)
RU (1) RU2009147281A (enExample)
WO (1) WO2008144761A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104593488B (zh) * 2007-05-21 2018-06-12 健泰科生物技术公司 用于鉴定和治疗狼疮的方法和组合物
BRPI0913778A2 (pt) * 2008-09-26 2015-10-20 Genentech Inc "métodos de identificação de lúpus, para prever a responsividade, de diagnóstico, para auxiliar o diagnóstico, usos de um agente terapêutico, métodos de identificação, métodos, métodos para selecionar um paciente, para avaliar se um sujeito nestá em risco de desenvolver lúpus, de diagnóstico de lúpus, para prognóstico de lúpus e para auxiliar o prognóstico"
US20100105061A1 (en) * 2008-10-29 2010-04-29 University Of Southern California Autoimmune genes identified in systemic lupus erythematosus (sle)
US20110319288A1 (en) * 2009-03-03 2011-12-29 Merck Serono S.A. Bank1 related snps and sle and/or ms susceptibility
KR101824744B1 (ko) * 2009-10-07 2018-03-15 제넨테크, 인크. 루푸스의 치료, 진단 및 모니터링 방법
CA2791962A1 (en) * 2010-03-01 2011-09-09 Alexion Pharmaceuticals, Inc. Methods and compositions for treating degos' disease
AU2012214417A1 (en) * 2011-02-10 2013-09-05 Genqual Corporation Methods of prognosing and administering treatment for inflammatory disorders
US20130317006A1 (en) 2012-05-24 2013-11-28 Amy Yasko Use of polymorphisms for identifying individuals at risk of developing autism
WO2015081052A1 (en) 2013-11-27 2015-06-04 Yasko Amy Use of polymorphisms for identifying individuals at risk of developing autism
CN108377651A (zh) * 2015-06-24 2018-08-07 牛津生物动力有限公司 染色体互相作用的检测
CN110459312B (zh) * 2018-05-07 2024-01-12 深圳华大生命科学研究院 类风湿性关节炎易感位点及其应用
US20230054595A1 (en) * 2019-12-18 2023-02-23 The Children's Hospital Of Philadelphia Novel druggable targets for the treatment of inflammatory diseases such as systemic lupus erythematosus (sle) and methods for diagnosis and treatment using the same
KR20240021336A (ko) 2022-08-09 2024-02-19 심재홍 수액 채취장치의 냉각기 구조
CN116030889B (zh) * 2023-02-16 2026-01-02 复旦大学 一种线粒体异质性分布中分配差异率计算的模型化方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683203A (en) 1984-04-14 1987-07-28 Redco N.V. Immobilized enzymes, processes for preparing same, and use thereof
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
IE61148B1 (en) 1988-03-10 1994-10-05 Ici Plc Method of detecting nucleotide sequences
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
CA2050918A1 (en) 1990-01-12 1991-07-13 Raju Kucherlapati Generation of xenogeneic antibodies
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69133476T2 (de) * 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
JP4468488B2 (ja) 1996-05-29 2010-05-26 コーネル・リサーチ・ファンデーション・インコーポレイテッド 組み合せたリガーゼ検出およびポリメラーゼ連鎖反応を用いる核酸配列相違の検出
DK1500329T3 (da) 1996-12-03 2012-07-09 Amgen Fremont Inc Humane antistoffer, der specifikt binder TNF-alfa
WO2001092579A2 (en) 2000-05-30 2001-12-06 Pe Corporation (Ny) Methods for detecting target nucleic acids using coupled ligation and amplification
US6900016B1 (en) 2000-09-08 2005-05-31 Applera Corporation Polymorphisms in known genes associated with inflammatory autoimmune disease, methods of detection and uses thereof
IL155450A0 (en) * 2000-10-20 2003-11-23 Expression Diagnostics Inc Leukocyte expression profiling
US7205106B1 (en) 2001-07-20 2007-04-17 Roche Molecular Systems, Inc. Association of polymorphisms in IL4-related genes with autoimmune disease
JP2003061677A (ja) * 2001-08-28 2003-03-04 Olympus Optical Co Ltd 全身性エリテマトーデスの感受性遺伝子およびその使用
US20030119004A1 (en) 2001-12-05 2003-06-26 Wenz H. Michael Methods for quantitating nucleic acids using coupled ligation and amplification
US7022476B2 (en) * 2002-02-26 2006-04-04 New York Society For Ruptured And Crippled Maintaining The Hospital For Special Surgery Human FcγRIIB gene polymorphisms for assessing development of systemic lupus erythematosus and compositions for use thereof
US7208274B2 (en) * 2002-03-01 2007-04-24 Ravgen, Inc. Rapid analysis of variations in a genome
US7811794B2 (en) 2003-03-18 2010-10-12 Celera Corporation Genetic polymorphisms associated with rheumatoid arthritis, methods of detection and uses thereof
WO2005086872A2 (en) * 2004-03-10 2005-09-22 Celera, An Applera Corporation Business Ptpn22 polymorphisms in diagnosis and therapy
WO2006097463A2 (en) * 2005-03-15 2006-09-21 Ares Trading S.A. Compositions and methods for treating and diagnosing inflammatory disorders
SI2327792T1 (sl) 2005-08-05 2013-12-31 Genentech, Inc. Postopki in sestavki za detektiranje avtoimunskih motenj
US20070269827A1 (en) * 2006-05-18 2007-11-22 Oklahoma Medical Research Foundation Predicting and Diagnosing Patients With Autoimmune Disease
CN104593488B (zh) * 2007-05-21 2018-06-12 健泰科生物技术公司 用于鉴定和治疗狼疮的方法和组合物
BRPI0913778A2 (pt) * 2008-09-26 2015-10-20 Genentech Inc "métodos de identificação de lúpus, para prever a responsividade, de diagnóstico, para auxiliar o diagnóstico, usos de um agente terapêutico, métodos de identificação, métodos, métodos para selecionar um paciente, para avaliar se um sujeito nestá em risco de desenvolver lúpus, de diagnóstico de lúpus, para prognóstico de lúpus e para auxiliar o prognóstico"

Also Published As

Publication number Publication date
US20110046094A1 (en) 2011-02-24
CN103298950B (zh) 2015-01-21
JP2010528590A (ja) 2010-08-26
EP3318643A3 (en) 2018-06-20
JP2018126146A (ja) 2018-08-16
KR101947093B1 (ko) 2019-02-12
AU2008254582A1 (en) 2008-11-27
CN103298950A (zh) 2013-09-11
CN104593488A (zh) 2015-05-06
HK1209459A1 (en) 2016-04-01
EP2158335A2 (en) 2010-03-03
HK1255086A1 (en) 2019-08-02
BRPI0811930B1 (pt) 2019-11-05
WO2008144761A2 (en) 2008-11-27
KR20190015629A (ko) 2019-02-13
MX343167B (es) 2016-10-26
CN108753946A (zh) 2018-11-06
HK1189246A1 (en) 2014-05-30
BRPI0811930B8 (pt) 2021-05-25
MX353428B (es) 2018-01-12
JP6080059B2 (ja) 2017-02-15
CN104593488B (zh) 2018-06-12
JP2015164426A (ja) 2015-09-17
KR101729431B1 (ko) 2017-04-21
KR20100021612A (ko) 2010-02-25
MX378733B (es) 2025-03-10
KR20170042831A (ko) 2017-04-19
EP2612924B1 (en) 2017-12-20
BRPI0811930A2 (pt) 2014-11-25
CA2690608A1 (en) 2008-11-27
WO2008144761A3 (en) 2009-07-02
RU2009147281A (ru) 2011-06-27
EP2612924A3 (en) 2013-10-23
JP5728226B2 (ja) 2015-06-03
EP3318643A2 (en) 2018-05-09
KR101651678B1 (ko) 2016-08-26
JP2017035088A (ja) 2017-02-16
KR20150133861A (ko) 2015-11-30
MX2009012531A (es) 2009-12-03
EP2612924A2 (en) 2013-07-10
ES2661249T3 (es) 2018-03-28
IL201949A0 (en) 2010-06-16

Similar Documents

Publication Publication Date Title
CA2690608C (en) Methods and compositions for identifying and treating lupus
US10053734B2 (en) Methods for treating, diagnosing, and monitoring lupus
US20100099101A1 (en) Methods for treating, diagnosing, and monitoring lupus
HK1209459B (zh) 用於鑒定和治療狼瘡的方法和組合物
HK1189246B (en) Methods and compositions for identifying and treating lupus

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130515